Plaquenil is used to treat or prevent malaria, a disease caused by parasites that enter the body through the bite of a mosquito. Malaria is common in areas such as Africa, South America, and Southern Asia. Plaquenil and humira interaction Chloroquine phosphate for sale The official website for TAFINLAR® dabrafenib capsules and MEKINIST® trametinib tablets. Find information about TAFINLAR + MEKINIST, the conditions it treats, and Important Safety Information. Phase I Trial of Trametinib and Hydroxychloroquine in Patients With Advanced Pancreatic Cancer THREAD Summary The purpose of this phase I trial is to study the side effects and best dose of hydroxychloroquine when given together with trametinib in treating patients with pancreatic cancer that has spread to nearby tissue, lymph nodes or other places in the body and cannot be removed by surgery. Search Results Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma Study Purpose The primary purpose of this study is to determine the maximum tolerated dose MTD and preliminary safety of hydroxychloroquine HCQ when administered in conjunction with oral dabrafenib and trametinib D+T in patients with advanced BRAF mutant melanoma. Plaquenil is also an antirheumatic medicine and is used to treat symptoms of rheumatoid arthritis and discoid or systemic lupus erythematosus. This medicine is not effective against all strains of malaria. Hydroxychloroquine and trametinib Trametinib and Hydroxychloroquine in Treating Patients with., Phase I Trial of Trametinib and Hydroxychloroquine in. Aralen lupusHair loss with plaquenilHydroxychloroquine with histoplasmosisHydroxychloroquine not working what nextMalarone chloroquine resistance Fig. 4 Treatment of a pancreatic cancer patient with trametinib plus hydroxychloroquine T/HCQ led to a reduction in tumor marker cancer antigen 19-9 CA19-9 and overall tumor burden. Protective autophagy elicited by RAF→MEK→ERK inhibition.. Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced.. Trametinib and Hydroxychloroquine in Treating Patients With.. Hydroxychloroquine sulfate is a colorless crystalline solid, soluble in water to at least 20 percent; chemically the drug is 2-4-7-Chloro-4-quinolylaminopentylethylamino ethanol sulfate 11. PLAQUENIL hydroxychloroquine sulfate tablets contain 200 mg hydroxychloroquine sulfate, equivalent to 155 mg base, and are for oral administration. This phase I trial studies the sides effects and best dose of hydroxychloroquine when given together with trametinib in treating patients with pancreatic cancer that has spread to nearby tissue, lymph nodes or other places in the body and cannot be removed by surgery. Trametinib may stop the growth. Dabrafenib and trametinib were discontinued for adverse reactions in 18% and 19% of patients, respectively. The recommended doses are dabrafenib 150 mg orally twice daily, approximately 12 hours.